&nbsp;

PhysicalHealthforGynecologicalCancerSurvivors.pdf

Jul 2024

Document

Physical-Health-for-Gynecological-Cancer_FR.pdf

Jul 2024

Politique de financement des essais cliniques pour les thérapies par lymphocytes T à récepteur antigénique chimérique (CAR-T)

Regimen

PEMB

Cancer Type:

Lung,

Non-Small Cell

Intent: Adjuvant

Funding:

New Drug Funding Program

Pembrolizumab - (Neo)adjuvant Therapy for Resectable Non-Small Cell Lung Cancer

Drugs Used:

pembrolizumab

Quick Link(s):

Regimen Monograph

Updated

Sep 2025

Document

unnecessary-biopsies.png

Sep 2024

Regimen

PEMB

Cancer Type:

Skin,

Melanoma

Intent: Neoadjuvant, Adjuvant

Funding:

New Drug Funding Program

Pembrolizumab - (Neo)adjuvant Treatment for Completely Resectable Stage III or IV Melanoma

Drugs Used:

pembrolizumab

Quick Link(s):

Regimen Monograph

Updated

Sep 2025

Regimen

PEME+CEMI(MNT)

Cancer Type:

Lung,

Non-Small Cell

Intent: Palliative

Funding:

New Drug Funding Program

Cemiplimab - In Combination with Chemotherapy for First-Line Treatment of Advanced Non-Small Cell Lung Cancer

Drugs Used:

pemetrexed,

cemiplimab

Quick Link(s):

Regimen Monograph

May 2025

Regimen

PEME+OSIM(MNT)

Cancer Type:

Lung,

Non-Small Cell

Intent: Palliative

Drugs Used:

pemetrexed,

osimertinib (Unfunded)

Quick Link(s):

Regimen Monograph

Oct 2024

Document

Postcard.zip

Nov 2024

Document

Poster.zip

Nov 2024

Regimen

PEMB+TRAS(MNT)

Cancer Type:

Gastrointestinal,

Gastric / Stomach

Intent: Palliative

Funding:

New Drug Funding Program

Pembrolizumab and Trastuzumab (Biosimilar) - First-line Treatment of Advanced HER2-Positive Gastric or Esophagogastric Junction Adenocarcinoma

New Drug Funding Program

Pembrolizumab and Trastuzumab (Biosimilar) - First-line Treatment of Advanced HER2-Positive Gastric or Esophagogastric Junction Adenocarcinoma

Drugs Used:

pembrolizumab,

trastuzumab